IL-17A levels are elevated in the CSF of relapsing-remitting MS (RRMS) patients and a combination of IL-17A and IL-6 may disrupt the BBB by decreasing the expression of tight junction-associated genes (33). Here, IL17A is linked to relapsing-remitting multiple sclerosis.